BLUF: Insilico Medicine, a biotechnology company, announced that the first ever AI-discovered and AI-designed drug, known as INS018_055, has entered Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis. The use of generative AI has significantly accelerated the drug discovery process, reducing costs and time. This milestone demonstrates the potential of AI-accelerated drug discovery to improve productivity in the medical industry.
Subscribe
Login
Please login to comment
0 Comments
Most Voted